FWM
VRTX icon

Filbrandt Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Filbrandt Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3K Buy
+17
New +$3.32K ﹤0.01% 167
2020
Q3 		– Sell
-10
Closed -$3K – 349
2020
Q2 		$3K Buy
+10
New +$2.71K ﹤0.01% 310

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Filbrandt Wealth Management's VRTX Position: Q3 2021 in Review

Filbrandt Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2021: 17 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #167 among its holdings. This is a return to the name: Filbrandt Wealth Management previously reported a position in VRTX as recently as Q2 2020.

Filbrandt Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Filbrandt Wealth Management held 17 shares of Vertex Pharmaceuticals worth $3K as of Q3 2021.
  • Vertex Pharmaceuticals was a new Filbrandt Wealth Management position in Q3 2021.
  • Vertex Pharmaceuticals made up ﹤0.01% of Filbrandt Wealth Management's portfolio in Q3 2021, its #167 holding.
  • Filbrandt Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Filbrandt Wealth Management's 13F filing for Q3 2021, filed 6 Oct 2021.